文献速递消化系统肿瘤

肿瘤生物学因素在诱导全身治疗后结直肠癌肝转移技术解剖可切除性评估中的作用:荷兰CAIRO5试验分析

The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial.
PubMed 文献 · Eur J Cancer · 2023-01-31

该研究基于3期CAIRO5试验中482例初始不可切除结直肠癌肝转移患者,评估肿瘤生物学因素对专家小组可切除性共识、二次可切除性及术后早期复发的影响。结果显示,仅肝转移灶数目(OR 1.09)和年龄(OR 1.03)与早期复发独立相关,肿瘤生物学因素无预测作用。

要点

  • 在482例初始不可切除CRLM患者中,240例(50%)接受完整局部治疗,其中75例(31%)出现早期复发且未再行局部治疗。
  • 肝转移灶数目(OR 1.09,95%CI 1.03-1.15)和年龄(OR 1.03,95%CI 1.00-1.07)与早期复发独立相关。
  • 肿瘤生物学因素(原发灶位置、同时性CRLM、CEA及RAS/BRAFV600E突变状态)未显示预测作用。

核心结论

  • 经诱导全身治疗后由专家小组选出的二次CRLM手术患者中,近三分之一出现仅适合姑息治疗的早期复发。
  • 肝转移灶数目和年龄有预测作用,但无肿瘤生物学因素有预测作用,提示在出现更好的生物标志物之前,可切除性评估主要仍是技术解剖决策。

研究设计与样本

  • 研究为3期CAIRO5试验的事后分析,纳入482例初始不可切除的结直肠癌肝转移患者。
  • 由肝脏专家小组每两个月进行可切除性评估;若小组外科医生间无共识(即对CRLM可切除或不可切除投票相同),则按多数意见得出结论。
  • 采用单因素和预设的多因素逻辑回归分析肿瘤生物学因素(原发灶位置、同时性CRLM、CEA及RAS/BRAFV600E突变状态)和技术解剖因素与小组共识、二次可切除性及早期复发(<6个月)且未行根治性重复局部治疗的关系。

主要发现

  • 全身治疗后,240例(50%)患者接受了CRLM完整局部治疗,其中75例(31%)出现早期复发且未行重复局部治疗。
  • 肝转移灶数目较高(OR 1.09,95%CI 1.03-1.15)和年龄(OR 1.03,95%CI 1.00-1.07)与早期复发且未行重复局部治疗独立相关。
  • 138例(52%)患者在局部治疗前小组外科医生间无共识;有共识和无共识患者的术后结局相当。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Large inter-surgeon variability exists in technical anatomical resectability assessment of colorectal cancer liver-only metastases (CRLM) following induction systemic therapy. We evaluated the role of tumour biological factors in predicting resectability and (early) recurrence after surgery for initially unresectable CRLM. METHODS: 482 patients with initially unresectable CRLM from the phase 3 CAIRO5 trial were selected, with two-monthly resectability assessments by a liver expert panel. If no consensus existed among panel surgeons (i.e. same vote for (un)resectability of CRLM), conclusion was based on majority. The association of tumour biological (sidedness, synchronous CRLM, carcinoembryonic antigen and RAS/BRAFV600E mutation status) and technical anatomical factors with consensus among panel surgeons, secondary resectability and early recurrence (<6 months) without curative-intent repeat local treatment was analysed by uni- and pre-specified multivariable logistic regression. RESULTS: After systemic treatment, 240 (50%) patients received complete local treatment of CRLM of which 75 (31%) patients experienced early recurrence without repeat local treatment. Higher number of CRLM (odds ratio 1.09 [95% confidence interval 1.03-1.15]) and age (odds ratio 1.03 [95% confidence interval 1.00-1.07]) were independently associated with early recurrence without repeat local treatment. In 138 (52%) patients, no consensus among panel surgeons was present prior to local treatment. Postoperative outcomes in patients with and without consensus were comparable. CONCLUSIONS: Almost a third of patients selected by an expert panel for secondary CRLM surgery following induction systemic treatment experience an early recurrence only amenable to palliative treatment. Number of CRLM and age, but no tumour biological factors are predictive, suggesting that until there are better biomarkers; resectability assessment remains primarily a technical anatomical decision.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bolhuis K, Bond MJG, Van Amerongen MJ, et al. The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial. Eur J Cancer. 2023. PMID: 36801606. doi:10.1016/j.ejca.2023.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。